Methyl CPG binding protein 2 (MECP2) duplication syndrome

Clinical trials for Methyl CPG binding protein 2 (MECP2) duplication syndrome explained in plain language.

Never miss a new study

Get alerted when new Methyl CPG binding protein 2 (MECP2) duplication syndrome trials appear

Sign up with your email to follow new studies for Methyl CPG binding protein 2 (MECP2) duplication syndrome, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Terminated 1

New hope for rare genetic disorder: drug ION440 enters human trials

Disease control Recruiting now

This study tests a new drug called ION440 in 48 people with MECP2 duplication syndrome, a rare genetic condition that causes intellectual disability and seizures. The drug is given via a spinal injection to see if it is safe and how the body processes it. Some participants will r…

Matched conditions: METHYL CPG BINDING PROTEIN 2 (MECP2) DUPLICATION SYNDROME

Phase 1/2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:00 UTC

Methyl CPG binding protein 2 (MECP2) duplication syndrome

Get alerted when new Methyl CPG binding protein 2 (MECP2) duplication syndrome trials appear

New hope for rare genetic disorder: drug ION440 enters human trials